We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioprogress | LSE:BPRG | London | Ordinary Share | GB0032681628 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 50.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:3595C BioProgress PLC 17 August 2007 For Immediate Release 17 August 2007 BioProgress plc ('BioProgress' or the 'Company') Trading update London UK, 17th August 2007, the Board of BioProgress (AIM: BPRG), the specialty pharmaceutical and healthcare company has noted the recent fall in its share price and whilst recognising the volatility in the UK stock market generally, provides the following update. Following the announcement on 28 June 2007 of the acquisition of Melbrosin, BioProgress is pleased to announce that the integration of the new business is progressing well. The core products are performing to plan and cross fertilisation of products into the other business units has commenced. New product development and partner programmes remain on course to deliver to the Company's expectations. The Board is confident that the strategy put into place is being executed to plan. The Company remains on track to achieve market expectations for 2007. For further information: BioProgress Plc + 44 (0) 20 7098 9881 Richard Trevillion, CEO Steve Martin, CDO Hiral Patel, CFO Buchanan Communications + 44 (0) 20 7466 5000 Rebecca Skye Dietrich Mark Court About BioProgress BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical and healthcare products. The business continues to develop innovative delivery mechanisms using its XGELTM polymer technology. For further information please go to www.bioprogress.com This information is provided by RNS The company news service from the London Stock Exchange END SPMPRMTTMMABBLR
1 Year Bioprogress Chart |
1 Month Bioprogress Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions